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Abstract: The presence of mast cells in human atherosclerotic plaques has been associated with 
adverse cardiovascular events. Mast cell activation, through the classical antigen sensitized-IgE 
binding to their characteristic Fcε-receptor, causes the release of their cytoplasmic granules. These 
granules are filled with neutral proteases such as tryptase, but also with histamine and pro-
inflammatory mediators. Mast cells accumulate in high numbers within human atherosclerotic 
tissue, particularly in the shoulder region of the plaque. These findings are largely based on 
immunohistochemistry, which does not allow for the extensive characterization of these mast cells 
and of the local mast cell activation mechanisms. In this study, we thus aimed to develop a new 
flow-cytometry based methodology in order to analyze mast cells in human atherosclerosis. We 
enzymatically digested 22 human plaque samples, collected after femoral and carotid 
endarterectomy surgery, after which we prepared a single cell suspension for flow cytometry. We 
were able to identify a specific mast cell population expressing both CD117 and the FcεR, and 
observed that most of the intraplaque mast cells were activated based on their CD63 protein 
expression. Furthermore, most of the activated mast cells had IgE fragments bound on their 
surface, while another fraction showed IgE-independent activation. In conclusion, we are able to 
distinguish a clear mast cell population in human atherosclerotic plaques, and this study 
establishes a strong relationship between the presence of IgE and the activation of mast cells in 
advanced atherosclerosis. Our data pave the way for potential therapeutic intervention through 
targeting IgE-mediated actions in human atherosclerosis. 
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1. Introduction 
Up to the present day, atherosclerosis, the main underlying pathology of acute cardiovascular 
syndromes like stroke or myocardial infarction, is the major cause of human mortality [1]. As in 
most pathological conditions, the response of the immune system is crucial in the advancement of 
atherosclerosis, with mast cells being key mediators in this process [2]. Mast cells are innate 
immune cells, unique for their notorious granular load release upon activation with antigen-
sensitized IgE fragments, in allergic reactions [3]. Aside from allergic inflammation, mast cells have 
long been established to play an important pro-inflammatory role in the development of 
atherosclerosis in experimental studies, as well as in human subjects [4]. Mast cells reside at low 
numbers in normal arterial tissue, however, their numbers increase in the arteries where a lipid-rich 
atherosclerotic plaque is formed [5]. In fact, as human atherosclerosis progresses, mast cells become 
increasingly activated and excrete their granules in the surrounding tissue [6]. The degranulated 
material consists mainly of proinflammatory cytokines, histamine, and neutral proteases, such as 
chymase and tryptase [7]. Mast cell activation is reported to augment plaque progression [8], 
enhance plaque destabilization [9], and increase the levels of intraplaque hemorrhage incidence 
[10]. Previous attempts to characterize mast cells and their protease content in human atheromata, 
by the means of immunohistochemistry, have revealed that mast cells comprise a heterogeneous 
population; the majority of cells contain only tryptase, while a smaller proportion contains chymase 
and tryptase [11]. Both of these proteases have been investigated in experimental studies of 
atherosclerosis. In these studies, tryptase has been implicated in atherosclerotic plaque 
destabilization [12], while the inhibition of chymase limited atherosclerotic plaque development 
and progression [13]. 
In human plaques, mast cells have furthermore been found to correlate with typical 
atherogenic immune populations, such as dendritic cells and T cells [14]. Importantly, in a human 
study of 270 patients, intraplaque mast cells emerged as the primary immune cell type to be 
positively associated with future cardiovascular events [15], and may thus actively contribute to 
atherosclerotic plaque destabilization. Until this day however, the means by which mast cells get 
activated inside atherosclerotic plaques have not been elucidated in full detail. However, it is 
suggested that the classical IgE-sensitized pathway [16,17] is involved to a certain extent. Moreover, 
there is increasing in vivo evidence that additional atherosclerosis-specific mechanisms can trigger 
mast cell activation, independently of IgE-binding [18,19], such as activation through Toll-like 
receptors (TLRs) [20], complement receptors [21], or neuropeptide [22] receptors. Thus far however, 
the proportional effect of these distinct pathways involved in atherosclerosis has not been clarified. 
The presence of mast cells has thus far only been established by means of 
immunohistochemical staining. While this provides important information regarding the location 
of mast cells in the lesion, this method is limited by the number of markers that can be used to 
identify a cell type and its activation status. To be able to characterize the mast cell population in 
human atherosclerotic lesions in more detail using multiple markers simultaneously, we aimed to 
develop a novel flow cytometry-based technique to identify the mast cell population in human 
atherosclerosis, and to determine its activation status. 
2. Methods 
2.1. Sample Collection and Processing 
The atherosclerotic plaque material of 22 anonymous human subjects was collected peri-
operatively from carotid (n = 10) and femoral (n = 12) artery endarterectomy (from July to December 
2016 at the Haaglanden Medical Center Westeinde, The Hague, The Netherlands). The handling of 
all of the human samples complied with the “Code for Proper Secondary Use of Human Tissue”, 
METC number 16-071. The plaque samples were placed in RPMI (Lonza, Breda, The Netherlands) 
directly after removal from the patient. The culprit part of the plaques was collected as described 
previously [23], and stored in Shandon Zinc Formal-Fixx (Thermo Scientific, Waltham, MA, USA) 
for histology purposes. The remainder (~90%) of the plaques were processed into single cell 
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suspensions by a 2-h digestion step in 37 °C, with an enzyme mix consisting of collagenase IV 
(Thermo Scientific, Waltham, MA, USA) and DNase (Sigma, Zwijndrecht, The Netherlands), as 
previously described [24]. Subsequently, the samples were filtered through a 70 μm cell strainer to 
obtain single cells, which were kept in RPMI/1% Fetal Calf Serum (FCS) until further analysis. 
2.2. Histology 
The culprit part of atherosclerotic samples was placed in Kristensen’s buffer for three to seven 
days for decalcification, after which the plaques were embedded in paraffin. Next, the plaques were 
sectioned in 5-μm thick sections using a microtome RM2235 (LEICA Biosystems, Amsterdam, The 
Netherlands). A Movat’s pentachrome staining was routinely performed, and subsequently, the 
plaques were analyzed for histological parameters, as described in Table 1 (three sections/plaque), 
based on the semiquantitative scoring systems of the AtheroExpress biobank [23] and the Oxford 
Plaque Study [25]. In short, the plaques were assessed for the presence of unstable plaque features 
such as the presence of a necrotic core, inflammatory cells, and intraplaque hemorrhage, as well as 
stable plaque features such as smooth muscle cell (SMC)-rich extracellular matrix (ECM). To 
identify the mast cells in the lesion, atherosclerotic plaque sections were immunohistochemically 
stained for tryptase using an alkaline phosphatase-conjugated antibody directed against tryptase 
(1:250, clone G3, Sigma, Zwijndrecht, The Netherlands), after which nitro-blue tetrazolium and 5-
bromo-4-chloro-3’-indolyphosphate were used as a substrate. Nuclear Fast Red was used as a 
counterstaining for the nuclei. For the morphologic analysis, slides were analyzed using a Leica 
DM-RE microscope (Leica Ltd., Cambridge, UK). 
Table 1. Semiquantitative grading scale for the histology score of human endarterectomy specimen. 
Grade 0 1 2 3 4 
Necrotic Core 
No sign of 
necrotic core 
<20% of the arterial 
area 
20%–40% of the 
arterial area 
40%–70% of the 
arterial area 
>70% 
Calcification No sign of 
calcification 
<10% of the arterial 
area 
10%–40% of the 
arterial area 








* A few small sized 




* Multiple small 
(~5) or medium 
sized (~10) 




* At least 1 large 
sized cluster (~15) of 
foam cells or foam 
cells scattered around 





No sign of 
cholesterol 
crystal 
<10% of the necrotic 
core 
10%–40% of the 
necrotic core 





No sign of 
neovasculari- 
zation 
<25 neovessels in the 
whole tissue 
25–50 neovessels 
in whole tissue 
>50 neovessels in the 
whole tissue  
Inflammatory 
Cells  





* A few (1 or 2) small 
sized (~50 cells) 
clusters of 
inflammatory cells or a 
few cells occasionally 
spread throughout the 
Intermediate  
 
* Multiple (~5) 
small sized (~50 





* At least 1 large 
sized (~100 cells) 
cluster of 
inflammatory cells or 
cells scattered around 
~70% of the arterial 
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arterial area area   
Shoulder Not 
detectable*  










No sign of IPH 
<10% IPH of the 
arterial area 
10%–40% IPH of 
the arterial area 








<20% of the ECM area 20%–40% of the 
ECM area 
>40% of the ECM area  
Luminal 
thrombosis 
No Yes (rupture)    
SMC—smooth muscle cell; ECM—extracellular matrix. 
2.3. Flow Cytometry 
The single plaque cells were stained with extracellular antibodies containing a fluorescent 
label, or were fixated and permeabilized (BD Biosciences, San Jose, CA, USA) for intracellular 
staining (Table 2). The fluorescently labeled samples were measured on a FACS Canto II (BD 
Biosciences, San Jose (CA), USA) or Cytoflex (Beckman Coulter, Miami, FL, USA), and were 
analyzed using FlowJo software (v10). 
Table 2. List of extracellular and intracellular antibodies used. 
Antibody Fluorochrome Clone Concentration Company 
Fixable Viability Dye eFluor 780 - 0.1μg/sample eBioscience 
CD45 PB 2D1 0.25μg/sample eBioscience 
FcεRIα APC/PE Cy7 AER-37 0.12 μg/sample eBioscience 
CD117 PercP Cy5.5 104D2 0.1μg/sample eBioscience 
CD63 PE H5C6 0.1μg/sample eBioscience 
IgE PE Cy7/FITC Ige21 0.25μg/sample eBioscience 
Tryptase/TPSAB1 PE - 0.1μg/sample LSBio 
2.4. Statistics 
All of the data are depicted using GraphPad Prism 7.00. The values were tested for normalcy. 
Upon non-Gaussian distribution, an unpaired Mann–Whitney U-test was performed. In the case of 
more than two groups, a one way-ANOVA analysis was used. Differences lower than p < 0.05 were 
considered statistically significant. 
3. Results 
We analyzed the culprit part of the carotid and femoral plaques for its histology characteristics, 
based on the Movat’s pentachrome staining (Figure 1A). The characteristics of the individual 
plaques and the assessment of the plaque stability parameters are shown in Figure 1B. Overall, the 
presence of a necrotic core, inflammatory cells, and intraplaque hemorrhage establish that the 
majority of the plaques can be classified as advanced, as expected. 
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Figure 1. Human plaque characteristics. (A) Examples of Movat’s pentachrome stained human 
endarterectomy plaques. (B) Assessment of the plaque stability parameters of the individual 
plaques used for mast cell flow cytometry. SMC—smooth muscle cell; ECM—extracellular matrix. 
Next, we prepared single cell suspensions of the remainder of the individual plaques, and 
stained the cells for the surface markers to be analyzed using flow cytometry. In Figure 2A, we 
demonstrate the gating strategy that we followed in order to detect the human intraplaque immune 
cells. Specifically, we pre-selected all of the cells from the debris present in the human plaques 
based on their size (forward scatter, FSC) and granularity (side scatter, SSC). Of these, single cells 
were further separated according to their width (FSC-W) and area (FSC-A). In addition, the 
viability was detected according to the negative signal for a fluorescent viability dye (FVD−). Viable 
white blood cells were identified according to the expression of the pan-leukocyte marker CD45. As 
the femoral plaques were generally bigger in size upon surgical removal compared with the carotid 
plaques, we were able to isolate more CD45+ immune cells from the femoral arteries (carotid: 12 × 
105 ± 4.7 × 105 leukocytes vs. femoral: 76 × 105 ± 27 × 105 leukocytes; Figure 2B). 
Within these cells, we detected the population of intraplaque mast cells based on the high 
expression of their characteristic markers FcεRIα, the receptor for IgE [26], and of CD117—the 
receptor for stem cell factor, a growth factor required for the end-stage maturation of mast cells [27] 
(Figure 2C). Accordingly, we observed that the percentage of mast cells out of all of the viable 
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leukocytes present inside the atherosclerotic plaques is 1.19% ± 0.31% for the carotid arteries (n = 9), 
and 1.32% ± 0.21% for the femoral arteries (n = 13) (Figure 2D). Of note, a number of leukocytes may 
have been retained in the excluded debris material. Nonetheless, we enumerated the viable cells 
after manual quantification using Trypan Blue in relation to the percentage of viable CD45+ cells 
observed according to our gating strategy. We detected that the carotid plaques consisted of a mean 
12 ± 5 × 103 mast cells, while the femoral plaques contained 94 ± 37 × 103 mast cells. Thus, because of 
the higher total number of leukocytes, we identified higher absolute mast cell numbers in the 
femoral plaques compared with the carotid plaques (Figure 2E). 
 
Figure 2. Mast cell content in human plaques. (A) Human plaque cell gating strategy using flow 
cytometry. Human intraplaque cells were selected based on their size and area. The viable cells 
were further separated according to the negative incorporation of fluorescent viability dye (FVD−). 
Immune cells were detected using the pan-leukocyte marker CD45+. (B) Both the femoral and 
carotid artery plaques contain CD45+ immune cells. (C) The human mast cell population was further 
classified using antibodies against the characteristic markers FcεRIα+ and CD117+. (D) Mast cell 
percentage inside human plaques isolated upon endarterectomy surgeries in carotid and femoral 
arteries. (E) Absolute mast cell numbers of human carotid and femoral artery samples. The data are 
depicted as mean ± standard error of the mean (SEM); (n = 10–12/grp). 
We proceeded to further characterize the human intraplaque cells with respect to their 
activation status. We therefore screened our cells for the expression of CD63, a lysosomal protein 
that fuses with the membrane upon the release of cellular content, and marks mast cell activation 
[28]. We detected 7.0 ± 3.5 × 103 CD63+ mast cells in carotid plaques, which indicates that about 56% 
of these cells are in an activated state, while the femoral plaques showed 57 ± 23 × 103 activated 
mast cells, at a total percentage of 61% (Figure 3A,B). As the mast cell activation in, for example 
allergic reactions, predominantly occurs via IgE bound to its receptor (FcεR), we also stained the 
cells for the levels of IgE bound on their surface, and observed that inside the carotid arteries 7.8 ± 
3.4 × 103 intraplaque mast cells, or approximately 63% of the total mast cell population, contained 
IgE, whereas in the femoral plaques 77 ± 36 × 103 mast cells, or 74% of all of the mast cells had IgE 
on their surface. Because IgE binding generally implies mast cell degranulation, we analyzed, 
within each arterial plaque sample, the population of mast cells that showed both bound IgE and 
CD63 expression (IgE+CD63+), as opposed to only IgE-binding (IgE+CD63−) and only a CD63 
expression (IgE−CD63+) (Figure 3B). We observed that 23.8% ± 3.7% of all human plaque mast cells 
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have IgE bound on their surface without expressing CD63, whereas the majority of mast cells, with 
40.0% ± 3.9%, appeared to have IgE bound on their surface, and had also undergone degranulation. 
Interestingly, a proportion of mast cells, namely 19.6% ± 2.9%, appeared to be activated without 
showing any IgE-fragments bound on their surface, suggesting that this mast cell fraction had been 
activated via alternative mast cell activation pathways. The IgE-activated population was however 
significantly higher than the cells subjected to non-IgE mediated activation (p = 0.0005), and also 
higher than the mast cell population that showed a binding of IgE without being activated (p = 
0.0067). When analyzing the carotid and femoral arteries separately, similar expression patterns 
were observed (Figure 3E), suggesting that intraplaque mast cell activation mechanisms do not 
differ much between plaque locations. 
 
Figure 3. Activation of human intraplaque mast cells. (A) Number of activated mast cells, as defined 
by marker CD63, inside the carotid and femoral artery human plaques. (B) Percentage of activated 
mast cells in human atherosclerotic plaques. (C) Percentage of IgE+ mast cells in human 
atherosclerotic plaques. (D) Percentage of IgE+CD63-, IgE+CD63+, and of IgE-CD63+ mast cells of both 
carotid and femoral human atherosclerotic plaques combined. (E) Percentage of IgE+CD63-, 
IgE+CD63+, and of IgE-CD63+ mast cells displayed separately for carotid and femoral arteries, 
showing a similar pattern per plaque location. Data are depicted as mean ± SEM; A, B, C, and E: n = 
10–12/grp; D: n = 22. 
As tryptase is the preferred marker to determine the presence of mast cells in tissue by means 
of immunohistochemistry (Figure 4A), we also quantified the CD117+FcεRI+ mast cell populations 
that contained tryptase in a smaller sample of the same patients using flow cytometry (n = 7). We 
determined that 6.8 ± 1.4 × 103 of the carotid intraplaque mast cells, and 71 ± 27 × 103 of the femoral 
intraplaque mast cells were stained positive for tryptase (Figure 4B). In Figure 4C, a flow cytometry 
plot of an atherosclerotic plaque with a low number of tryptase+ mast cells (left panel) and one with 
a very high number of tryptase+ mast cells (right panel) are shown. As not all intraplaque mast cells 
seem to stain positive for tryptase, these data indicate that one may underestimate the number of 
mast cells using immunohistochemistry. In addition, the amount of tryptase+ mast cells in the 
plaque can apparently differ between patients, which may be caused by recent degranulation of the 
intraplaque mast cells. However, this remains to be further investigated in larger patient 
populations. 
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Figure 4. Tryptase content of mast cells in human atherosclerotic plaques. (A) Immunohistochemical 
tryptase staining of a human atherosclerotic plaque. Arrows indicate activated mast cells. (B) 
Number (left panel) and percentage (right panel) of mast cells containing tryptase in human carotid 
and femoral arteries based on flow cytometry. (C) Flow cytometry plot examples of tryptase+ mast 
cells, that is, left panel: low tryptase expression (7% of the mast cell population) vs. right panel: high 
tryptase expression (94% of the mast cell population). Values are depicted as mean ± SEM. 
4. Discussion 
In this study, we provide a novel flow cytometry-based approach to identify and characterize 
the mast cells in human atherosclerotic plaques. We classified ~1% of the total CD45+ leukocyte 
population obtained from the plaque tissue as mast cells, based on the CD117 and FcεRI expression. 
Previous data have established that these mast cells, although present in relatively low numbers in 
the plaque, can have a severe impact on plaque stability and on the risk of future cardiovascular 
events [15]. The majority of the mast cells present in arteries with advanced atherosclerosis are 
activated through IgE-binding, while a smaller fraction can undergo non-IgE-dependent activation. 
While IgE levels in the circulation [17] have been linked to increased incidence of acute 
cardiovascular events, and IgE fragments have been reported inside human atheromatic tissue [16], 
up until now, it was not clear to what extent this pathway affects mast cell activation in the area. 
Our data confirm that most mast cells present in the atherosclerotic plaques are activated [5,10], as 
it has been shown previously, specifically, for the shoulder region. We show here that the main 
activating mechanism is through classical antigen-sensitized IgE binding on their surface Fcε-
receptors. In addition, we show that a small proportion of cells bind IgE without undergoing 
activation. The circulating IgE can thus bind on the surface of the intraplaque mast cells and 
sensitize them prior to antigen binding. The exact antigenic fragment that may cause intraplaque 
mast cell activation has not yet been identified, but the binding of lipid-specific antigenic fragments 
may be a possible mechanism [20]. Furthermore, the detection of IgE fragments inside the plaque 
tissue confirms that these fragments can surpass the endothelial wall and accumulate in the plaque 
area, which may explain why circulating IgE levels correlate with end-stage cardiovascular events 
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like atherothrombosis [29] and myocardial infarction [30]. Therefore, it is reasonable to 
acknowledge IgE as an important risk factor in cardiovascular episodes, even though it still remains 
to be elucidated whether it is a causative element [31]. In addition, our data raise an interesting 
question regarding patients who suffer from other syndromes with increased circulating IgE levels. 
The development of atherosclerosis is a chronic process, which spans from the formation of a fatty 
streak, during an individual’s teenage years, and may result in an unfortunate acute event of an 
end-stage plaque rupture and vessel occlusion [32]. In the course of those years, a fraction of 
humans may be diagnosed with allergic inflammatory conditions, associating with high levels of 
circulating IgE [33]. This may mean that IgE has an increased chance to migrate through the 
endothelium and bind the intraplaque mast cells, raising the likelihood for a future cardiovascular 
event. In fact, there is compiling evidence that allergic asthma and atherosclerosis are linked [34], 
and mast cells are seemingly paramount in this [33]. In addition, patients with a genetic condition 
called hyper-IgE syndrome have recently been demonstrated to show signs of subclinical coronary 
atherosclerosis [35], and patients with systemic mastocytosis were recently described with a higher 
prevalence of cardiovascular disease events as compared to controls [36]. Interestingly, our group 
has demonstrated that the mast cell stabilizer cromolyn acts in a protective manner in 
atherosclerosis experimental studies [37]. Therefore, a mast cell stabilization approach may be an 
interesting preventive strategy in individuals who show high circulating IgE levels, but who have 
not yet been diagnosed with cardiovascular disease. In addition, we identified a group of mast cells 
that are activated without IgE binding, which suggests that this activation pathway is not the only 
way by which mast cells are activated in human atherosclerosis. We have previously established, in 
experimental atherosclerosis models, that mast cells in the vessel wall can be activated via 
neuropeptides such as Substance P [22] or Neuropeptide Y [38], or via complement components 
such as C5a [21]. These factors have also been shown to be present in human lesions [21,22]. It 
however remains to be established which of its receptors may induce mast cell activation in human 
atherosclerosis. The technical approach described in this study may be able to provide answers to 
these questions, by, for example, analyzing the expression of specific activating receptors on the 
intraplaque mast cells. It is still unclear what this implies in terms of mediator release. It would be 
interesting to further characterize the intracellular content of these cells to examine whether 
different activation pathways lead to the release of different proteases and cytokines, and how this 
may possibly affect the surrounding environment. Using this technique on a larger patient cohort 
may also reveal whether mast cell activation is affected by gender. A larger patient population will 
also allow for determining whether mast cell numbers or activation status relate to specific 
atherosclerotic plaque characteristics. 
Our data provide an additional important point of attention when using tryptase-based 
immunohistochemistry to identify mast cells in tissue. Our flow cytometry data provide evidence 
that not all mast cells stain positive for tryptase, which can be explained by the fact that the recently 
degranulated mast cells may have released their tryptase content. One should therefore keep in 
mind that when using tryptase-immunohistochemistry only, the number of (activated) mast cells in 
the tissue may be an underestimation, and one may opt for a second quantification method, for 
example, a flow cytometry-based method using multiple markers. 
In conclusion, in this study, we made use of flow cytometry to characterize mast cells in the 
advanced atherosclerotic plaques of human subjects. We confirm that the major pathway for the 
activation of mast cells inside the plaque tissue is IgE-mediated, and that the intraplaque mast cells 
are highly activated. This is particularly important, as it suggests that already available modes of 
therapy like mast cell stabilization agents [39] or anti-IgE treatment [40] may prove beneficial in 
patients suffering from atherosclerosis. We expect that larger scale patient studies and the analysis 
of more characterization markers, for instance through mass cytometry, will reveal new pathways 
via which mast cells may act in atherosclerosis, opening new ways to intervene in cardiovascular 
disease. 
Author Contributions: conceptualization, E.K., A.W., J.K., and I.B.; methodology, E.K, B.S., A.W., and I.B.; 
validation, M.R.d.V. and I.B.; formal analysis, E.K.; investigation, E.K., M.A.C.D., M.R.d.V., K.E.M., A.M.G., 
Cells 2019, 8, 334 10 of 12 
M.D.S., B.S., J.v.D., A.C.F.; data curation, E.K., A.W., and I.B.; writing (original draft preparation), E.K. and I.B.; 
writing (review and editing), all of the authors; supervision, H.J.S., J.K., and P.H.A.Q.; project administration, 
A.W. and I.B.; funding acquisition, J.K. and I.B. 
Funding: This project is funded by grant 95105013 (program translational research from ZonMW and the 
Dutch Heart Foundation). 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Benjamin, E.J.; Blaha, M.J.; Chiuve, S.E.; Cushman, M.; Das, S.R.; Deo, R.; de Ferranti, S.D.; Floyd, J.; 
Fornage, M.; Gillespie, C.; et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the 
American Heart Association. Circulation 2017, 135, e146–e603. 
2. Bot, I.; Shi, G.-P.; Kovanen, P.T. Mast cells as effectors in atherosclerosis. Arterioscler. Thromb. Vasc. 
Biol. 2015, 35, 265–271. 
3. Amin, K. The role of mast cells in allergic inflammation. Respir. Med. 2012, 106, 9–14. 
4. Shi, G.-P.; Bot, I.; Kovanen, P.T. Mast cells in human and experimental cardiometabolic diseases. Nat. 
Rev. Cardiol. 2015, 2, 643–658. 
5. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Accumulation of activated mast cells in the shoulder region 
of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994, 90, 
1669–1678. 
6. Kovanen, P.T.; Kaartinen, M.; Paavonen, T. Infiltrates of activated mast cells at the site of coronary 
atheromatous erosion or rupture in myocardial infarction. Circulation 1995, 92, 1084–1088. 
7. Bot, I.; Biessen, E.A.L. Mast cells in atherosclerosis. Thromb. Haemost. 2011, 106, 820–826. 
8. Ramalho, L.S.; Oliveira, L.F.; Cavellani, C.L.; Ferraz, M.L.; de Oliveira, F.A.; Miranda Corrêa, R.R.; de 
Paula Antunes Teixeira, V.; De Lima Pereira, S.A. Role of mast cell chymase and tryptase in the 
progression of atherosclerosis: Study in 44 autopsied cases. Ann. Diagn. Pathol. 2013, 17, 28–31. 
9. Mayranpaa, M.I.; Heikkila, H.M.; Lindstedt, K.A.; Walls, A.F.; Kovanen, P.T. Desquamation of human 
coronary artery endothelium by human mast cell proteases: Implications for plaque erosion. Coron. 
Artery Dis. 2006, 17, 611–621. 
10. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Mast cells accompany microvessels in human coronary 
atheromas: Implications for intimal neovascularization and hemorrhage. Atherosclerosis 1996, 123, 
123–131. 
11. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Mast cells of two types differing in neutral protease 
composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing 
mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. Arterioscler. Thromb. 
Vasc. Biol. 1994, 14, 966–972. 
12. Zhi, X.; Xu, C.; Zhang, H.; Tian, D.; Li, X.; Ning, Y.; Yin, L. Tryptase promotes atherosclerotic plaque 
haemorrhage in ApoE-/- mice. PLoS One 2013, 8, e60960. 
13. Bot, I.; Bot, M.; van Heiningen, S.H.; van Santbrink, P.J.; Lankhuizen, I.M.; Hartman, P.; Gruener, S.; 
Hilpert, H.; van Berkel, T.J.; Fingerle, J.; et al. Mast cell chymase inhibition reduces atherosclerotic 
plaque progression and improves plaque stability in ApoE-/- mice. Cardiovasc Res. 2011, 89, 244–252. 
14. Rohm, I.; Sattler, S.; Atiskova, Y.; Kretzschmar, D.; Pistulli, R.; Franz, M.; Jung, C.; Mall, G.; Kronert, 
T.; Schulze, P.C.; et al. Increased Number of Mast Cells in Atherosclerotic Lesions Correlates with the 
Presence of Myeloid but not Plasmacytoid Dendritic Cells as well as Pro-inflammatory T Cells. Clin. 
Lab. 2016, 62, 2293–2303. 
15. Willems, S.; Vink, A.; Bot, I.; Quax, P.H.; de Borst, G.J.; de Vries, J.P.; van de Weg, S.M.; Moll, F.L.; 
Kuiper, J.; Kovanen, P.T.; et al. Mast cells in human carotid atherosclerotic plaques are associated with 
intraplaque microvessel density and the occurrence of future cardiovascular events. Eur. Heart J. 2013, 
34, 3699–3706. 
16. Wang, J.; Cheng, X.; Xiang, M.X.; Alanne-Kinnunen, M.; Wang, J.A.; Chen, H.; He, A.; Sun, X.; Lin, Y.; 
Tang, T.T.; et al. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and 
promotes atherogenesis in Apoe-/- mice. J. Clin. Invest. 2011, 121, 3564–3577. 
17. Guo, X.; Yuan, S.; Liu, Y.; Zeng, Y.; Xie, H.; Liu, Z.; Zhang, S.; Fang, Q.; Wang, J.; Shen, Z. Serum IgE 
levels are associated with coronary artery disease severity. Atherosclerosis 2016, 251, 355–360. 
Cells 2019, 8, 334 11 of 12 
18. Kelley, J.; Hemontolor, G.; Younis, W.; Li, C.; Krishnaswamy, G.; Chi, D.S. Mast cell activation by 
lipoproteins. Methods Mol. Biol. 2006, 315, 341–348. 
19. Yu, Y.; Blokhuis, B.R.; Garssen, J.; Redegeld, F.A. Non-IgE mediated mast cell activation. Eur. J. 
Pharmacol. 2016, 778, 33–43. 
20. Meng, Z.; Yan, C.; Deng, Q.; Dong, X.; Duan, Z.M.; Gao, D.F.; Niu, X.L. Oxidized low-density 
lipoprotein induces inflammatory responses in cultured human mast cells via Toll-like receptor 4. 
Cell. Physiol. Biochem. 2013, 31, 842–853. 
21. de Vries, M.R.; Wezel, A.; Schepers, A.; van Santbrink, P.J.; Woodruff, T.M.; Niessen, H.W.; 
Hamming, J.F.; Kuiper, J.; Bot, I.; Quax, P.H. Complement factor C5a as mast cell activator mediates 
vascular remodelling in vein graft disease. Cardiovasc. Res. 2013, 97, 311–320. 
22. Bot, I.; de Jager, S.C.; Bot, M.; van Heiningen, S.H.; de Groot, P.; Veldhuizen, R.W.; van Berkel, T.J.; 
von der Thüsen, J.H.; Biessen, E.A. The neuropeptide substance P mediates adventitial mast cell 
activation and induces intraplaque hemorrhage in advanced atherosclerosis. Circ. Res. 2010, 106, 89–
92. 
23. Verhoeven, B.A.; de Vries, J.P.; Pasterkamp, G.; Ackerstaff, R.G.; Schoneveld, A.H.; Velema, E.; de 
Kleijn, D.P.; Moll, F.L. Carotid atherosclerotic plaque characteristics are associated with 
microembolization during carotid endarterectomy and procedural outcome. Stroke 2005, 36, 1735–
1740. 
24. Van Brussel, I.; Ammi, R.; Rombouts, M.; Cools, N.; Vercauteren, S.R.; De Roover, D.; Hendriks, 
J.M.H.; Lauwers, P.; Van Schil, P.E.; Schrijvers, D.M. Fluorescent activated cell sorting: An effective 
approach to study dendritic cell subsets in human atherosclerotic plaques. J. Immunol. Methods 2015, 
417, 76–85. 
25. Lovett, J.K.; Gallagher, P.J.; Hands, L.J.; Walton, J.; Rothwell, P.M. Histological correlates of carotid 
plaque surface morphology on lumen contrast imaging. Circulation 2004, 110, 2190–2197. 
26. Burd, P.R.; Rogers, H.W.; Gordon, J.R.; Martin, C.A.; Jayaraman, S.; Wilson, S.D.; Dvorak, A.M.; Galli, 
S.J.; Dorf, M.E. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen 
express multiple cytokines. J. Exp. Med. 1989, 170, 245–257. 
27. Tsai, M.; Takeishi, T.; Thompson, H.; Langley, K.E.; Zsebo, K.M.; Metcalfe, D.D.; Geissler, E.N.; Galli, 
S.J. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem 
cell factor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 6382–6386. 
28. Kraft, S.; Jouvin, M.H.; Kulkarni, N.; Kissing, S.; Morgan, E.S.; Dvorak, A.M.; Schröder, B.; Saftig, P.; 
Kinet, J.P. The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and 
anaphylaxis. J. Immunol. 2013, 191, 2871–2878. 
29. Sinkiewicz, W.; Błazejewski, J.; Bujak, R.; Zekanowska, E.; Sobański, P.; Kubica, J.; Dudziak, J.; 
Karasek, D.; Małyszka, P.; Balak, W.; et al. Immunoglobulin E as a marker of the atherothrombotic 
process in patients with acute myocardial infarction. Cardiol. J. 2007, 14, 266–273. 
30. Langer, R.D.; Criqui, M.H.; Feigelson, H.S.; McCann, T.J.; Hamburger, R.N. IgE predicts future 
nonfatal myocardial infarction in men. J. Clin. Epidemiol. 1996, 49, 203–209. 
31. Lippi, G.; Cervellin, G.; Sanchis-Gomar, F. Immunoglobulin E (IgE) and ischemic heart disease. Which 
came first, the chicken or the egg? Ann. Med. 2014, 46, 456–463. 
32. Insull, W.J. The pathology of atherosclerosis: Plaque development and plaque responses to medical 
treatment. Am. J. Med. 2009, 122, S3–S14. 
33. Laske, N.; Bunikowski, R.; Niggemann, B. Extraordinarily high serum IgE levels and consequences for 
atopic phenotypes. Ann. Allergy. Asthma Immunol. 2003, 91, 202–204. 
34. Wang, L.; Gao, S.; Xu, W.; Zhao, S.; Zhou, J.; Wang, N.; Yuan, Z. Allergic asthma accelerates 
atherosclerosis dependent on Th2 and Th17 in apolipoprotein E deficient mice. J. Mol. Cell. Cardiol. 
2014, 72, 20–27. 
35. Abd-Elmoniem, K.Z.; Ramos, N.; Yazdani, S.K.; Ghanem, A.M.; Holland, S.M.; Freeman, A.F.; Gharib, 
A.M. Coronary atherosclerosis and dilation in hyper IgE syndrome patients: Depiction by magnetic 
resonance vessel wall imaging and pathological correlation. Atherosclerosis 2017, 258, 20–25. 
36. Indhirajanti, S.; van Daele, P.L.A.; Bos, S.; Mulder, M.T.; Bot, I.; Roeters van Lennep, J.E. Systemic 
mastocytosis associates with cardiovascular events despite lower plasma lipid levels. Atherosclerosis 
2018, 268, 152–156. 
37. Bot, I.; de Jager, S.C.; Zernecke, A.; Lindstedt, K.A.; van Berkel, T.J.; Weber, C.; Biessen, E.A. 
Cells 2019, 8, 334 12 of 12 
Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-
deficient mice. Circulation 2007, 115, 2516–2525. 
38. Lagraauw, H.M.; Westra, M.M.; Bot, M.; Wezel, A.; van Santbrink, P.J.; Pasterkamp, G.; Biessen, E.A.; 
Kuiper, J.; Bot, I. Vascular neuropeptide Y contributes to atherosclerotic plaque progression and 
perivascular mast cell activation. Atherosclerosis 2014, 235, 196–203. 
39. Finn, D.F.; Walsh, J.J. Twenty-first century mast cell stabilizers. Br. J. Pharmacol. 2013, 170, 23–37. 
40. Logsdon, S.L.; Oettgen, H.C. Anti-IgE therapy: Clinical utility and mechanistic insights. Curr. Top. 
Microbiol. Immunol. 2015, 388, 39–61. 
 
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
